GB201703062D0 - Stabilized antibody protein solutions - Google Patents
Stabilized antibody protein solutionsInfo
- Publication number
- GB201703062D0 GB201703062D0 GBGB1703062.8A GB201703062A GB201703062D0 GB 201703062 D0 GB201703062 D0 GB 201703062D0 GB 201703062 A GB201703062 A GB 201703062A GB 201703062 D0 GB201703062 D0 GB 201703062D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibody protein
- protein solutions
- stabilized antibody
- stabilized
- solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703062.8A GB201703062D0 (en) | 2017-02-24 | 2017-02-24 | Stabilized antibody protein solutions |
| JP2019546176A JP2020508331A (ja) | 2017-02-24 | 2018-02-23 | 安定化された抗体溶液 |
| US16/487,990 US20200023061A1 (en) | 2017-02-24 | 2018-02-23 | Stabilized antibody solutions |
| ES18708189T ES3017936T3 (en) | 2017-02-24 | 2018-02-23 | Stabilized antibody solutions |
| PCT/GB2018/050481 WO2018154320A1 (en) | 2017-02-24 | 2018-02-23 | Stabilized antibody solutions |
| EP18708189.8A EP3585360B1 (en) | 2017-02-24 | 2018-02-23 | Stabilized antibody solutions |
| JP2023022283A JP2023071755A (ja) | 2017-02-24 | 2023-02-16 | 安定化された抗体溶液 |
| US18/243,767 US20230414753A1 (en) | 2017-02-24 | 2023-09-08 | Stabilized antibody protein solutions |
| JP2025018097A JP2025087696A (ja) | 2017-02-24 | 2025-02-06 | 安定化された抗体溶液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703062.8A GB201703062D0 (en) | 2017-02-24 | 2017-02-24 | Stabilized antibody protein solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201703062D0 true GB201703062D0 (en) | 2017-04-12 |
Family
ID=58544129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1703062.8A Ceased GB201703062D0 (en) | 2017-02-24 | 2017-02-24 | Stabilized antibody protein solutions |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200023061A1 (https=) |
| EP (1) | EP3585360B1 (https=) |
| JP (3) | JP2020508331A (https=) |
| ES (1) | ES3017936T3 (https=) |
| GB (1) | GB201703062D0 (https=) |
| WO (1) | WO2018154320A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
| AU2020401034B2 (en) * | 2019-12-12 | 2024-08-29 | Eli Lilly And Company | Methods for viral inactivation by environmentally compatible detergents |
| US20240374720A1 (en) * | 2020-05-29 | 2024-11-14 | Amgen Inc. | Antibody formulations and uses thereof |
| CN111665352B (zh) * | 2020-06-23 | 2024-05-17 | 广州市丹蓝生物科技有限公司 | 一种储存剂及由其制备的抗体溶液制剂及其应用 |
| US20240166718A1 (en) * | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CN1703233A (zh) * | 2002-07-12 | 2005-11-30 | 米德列斯公司 | 防止蛋白氧化降解的方法和组合物 |
| ES2569409T3 (es) | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| TW200831129A (en) * | 2006-10-06 | 2008-08-01 | Amgen Inc | Stable formulations |
| EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| NZ595526A (en) * | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| RU2011126338A (ru) | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| GB2499015A (en) | 2012-02-03 | 2013-08-07 | Reckitt Benckiser Nv | Detergent dispensing device. |
| EP3237000A1 (en) * | 2014-12-23 | 2017-11-01 | Pfizer Inc | Stable aqueous antibody formulation for anti tnf alpha antibodies |
| MX2017009759A (es) * | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
-
2017
- 2017-02-24 GB GBGB1703062.8A patent/GB201703062D0/en not_active Ceased
-
2018
- 2018-02-23 WO PCT/GB2018/050481 patent/WO2018154320A1/en not_active Ceased
- 2018-02-23 EP EP18708189.8A patent/EP3585360B1/en active Active
- 2018-02-23 US US16/487,990 patent/US20200023061A1/en not_active Abandoned
- 2018-02-23 ES ES18708189T patent/ES3017936T3/es active Active
- 2018-02-23 JP JP2019546176A patent/JP2020508331A/ja active Pending
-
2023
- 2023-02-16 JP JP2023022283A patent/JP2023071755A/ja active Pending
-
2025
- 2025-02-06 JP JP2025018097A patent/JP2025087696A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018154320A1 (en) | 2018-08-30 |
| EP3585360C0 (en) | 2025-01-22 |
| JP2025087696A (ja) | 2025-06-10 |
| EP3585360A1 (en) | 2020-01-01 |
| JP2020508331A (ja) | 2020-03-19 |
| EP3585360B1 (en) | 2025-01-22 |
| US20200023061A1 (en) | 2020-01-23 |
| ES3017936T3 (en) | 2025-05-14 |
| JP2023071755A (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905966B (en) | Anti-lag3 antibodies | |
| IL268517A (en) | Anti-tigit antibodies | |
| SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
| SG11202000660QA (en) | Anti-tigit antibodies | |
| ZA202002141B (en) | Anti-transthyretin antibodies | |
| PT3625259T (pt) | Anticorpos anti-sirpalfa | |
| GB201709808D0 (en) | Antibodies | |
| GB201703063D0 (en) | Stabilized antibody protein solutions | |
| GB201601073D0 (en) | Antibodies | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| GB201703062D0 (en) | Stabilized antibody protein solutions | |
| ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
| GB201720970D0 (en) | Antibodies | |
| IL273529A (en) | Anti-PACAP antibody | |
| IL271067A (en) | Anti-trkb antibodies | |
| IL260083A (en) | Antibody against myl9 | |
| SI3456736T1 (sl) | Variante protitelesa | |
| ZA202001830B (en) | Antibody variants | |
| IL272951A (en) | antibody variants | |
| GB201711785D0 (en) | Antibodies | |
| GB201709592D0 (en) | Antibody | |
| GB201717006D0 (en) | Anti-OPG antibodies | |
| HK40015837A (en) | Cysteine peptide-enabled antibodies | |
| GB201709818D0 (en) | Antibodies | |
| GB201703071D0 (en) | Antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |